Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

The effect of glucose-dependent insulinotropic polypeptide infused at physiological concentrations on the release of insulin in man

Summary

Blood glucose and the responses of insulin and glucose-dependent insulinotropic polypeptide (GIP) were measured in 12 healthy, normal weight subjects after drinking 50g glucose. On a subsequent occasion each subject was given a simultaneous infusion of GIP and glucose to mimic the plasma concentrations observed in the first test. The peak GIP concentration after oral glucose was 22.3±1.9pmol/l (mean±SEM), but was higher after GIP infusion at 36.3±4.6pmol/l, (p<0.005). The blood glucose levels following oral glucose peaked at 6.3 ±0.5 mmol/l which'was the same as seen after intravenous glucose. The insulin response to oral glucose was, however, far higher (431.3±58.2pmol/l) than that obtained after GIP and glucose infusion (191.6 ±30.9 pmol/l, p<0.001). Thus it has not proved possible to explain completely the oral enhancement of insulin release by the action of GIP alone.

References

  1. 1.

    Cleator IGM, Gourlay RH (1975) Release of immunoreactive gastric inhibitory polypeptide (IR-GIP) by oral ingestion of food substances. Am J Surg 13:128–135

  2. 2.

    Dupre J, Ross SA, Watson D, Brown JC (1973) Stimulation of insulin secretion by gastric inhibitory polypeptide in man. J Clin Endocrinol 37:826–828

  3. 3.

    Andersen DK, Elahi D, Brown JC, Tobin JD, Andres R (1978) Oral glucose augmentation of insulin release. J Clin Invest 62:152–161

  4. 4.

    Creutzfeldt W (1979) The incretin concept today. Diabetologia 16:75–85

  5. 5.

    Sarson DL, Bryant MG, Bloom SR (1980) A radioimmunoassay of gastric inhibitory polypeptide in human plasma. J Endocrinol 85:487–496

  6. 6.

    Holohan KW, Murphy RF, Flanagan RWJ, Buchanan KD, Elmore DT (1973) Enzymatic iodination of the histidyl residue of secretin: a radioimmunoassay of the hormone. Biochim Biophys Acta 322:178–180

  7. 7.

    Alford FP, Bloom SR, Nabarro JDN (1977) Glucagon levels in normal and diabetic subjects: use of a specific immunoabsorbent for glucagon radioimmunoassay. Diabetologia 13:1–6

  8. 8.

    Elahi D, Andersen DK, Brown JC, Debas HT, Herschcopf RJ, Raizes RS, Tobin J, Andres R (1979) Pancreatic alpha and beta cell responses to gastric inhibitory polypeptide in normal man during controlled glycaemia. Am J Physiol 237:E185-E191

  9. 9.

    Brown JC, Dryburgh JR, Ross SA, Dupre J (1975) Identification and actions of gastric inhibitory polypeptide. Rec Progr Horm Res 31:487–532

  10. 10.

    BestermanHS, BloomSR, Sarson DL, Blackburn AM, Johnston DI, Patel HR, Stewart JS, Modigliani R, Guerin S, Mallinson CN (1978) Characteristic gut hormone profile in coeliac disease. Lancet 1:785–788

  11. 11.

    Crockett SE, Mazzaferri EL, Cataland S (1976) Gastric inhibitory polypeptide in maturity-onset diabetes mellitus. Diabetes 25:931–935

Download references

Author information

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Sarson, D.L., Wood, S.M., Holder, D. et al. The effect of glucose-dependent insulinotropic polypeptide infused at physiological concentrations on the release of insulin in man. Diabetologia 22, 33–36 (1982). https://doi.org/10.1007/BF00253866

Download citation

Key words

  • Glucose-dependent insulinotropic polypeptide
  • gastric inhibitory polypeptide (GIP)
  • insulin
  • blood glucose
  • enteroinsular axis
  • incretin